A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study

• मुख्य लेखकों: Tadao Akizawa (लेखक), Masaomi Nangaku (लेखक), Takuhiro Yamaguchi (लेखक), Ryosuke Koretomo (लेखक), Kazuo Maeda (लेखक), Yuya Miyazawa (लेखक), Hideki Hirakata (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Karger Publishers, 2021-07-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Introduction: Enarodustat (JTZ-951) is a new oral hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). We conducted a phase 3 study to compare the efficacy and safety of enarodustat with darbepoetin alfa (DA) in Japanese anemic patients w...